INVO Bioscience, Inc. announced that it has entered into securities purchase agreement with new investor NAYA Biosciences, Inc. to issue 1,000,000 shares of the Company?s Series A non convertible Preferred Stock at a purchase price of $5.00 per share for the gross proceeds of $5,000,000 on December 29, 2023. The investor purchases will be made through tranches in accordance with the following schedule (1) $500,000 no later than Dec 29, 2023; (2) $500,000 no later than January 19, 2024; (3) $500,000 no later than February 2, 2024; (4) $500,000 no later than February 16, 2024; and (5) an additional amount as may be required prior to closing of the previously announced merger by and among the Company. The Company sold the Series A Preferred Stock pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.